Welcome - Home - Register - Login - Help/FAQ - 0 items

Search Enter keywords, a title or a report id number below. In All Categories --------------------- Telecom & Computing Business & Finance Mfg & Construction Pharma & Healthcare Consumer & Retail Gov & Public Sector Energy & Transport Country Reports Company Reports --------------------- Transcripts Advanced      Select a currency for use throughout the site Australia Dollars Canada Dollars Euro Japan Yen Sweden Kroner Switzerland Francs UK Pounds US Dollars Viewing report Order by Fax Printer Friendly PDF Brochure Send to Friend Enquire before Buying Hard Copy Electronic (PDF) Enterprisewide Undiagnosed Sleep Disorder Market Offers Growth Opportunities Koncept Analytics, April 2008, Pages: 31   Description     Table of Contents     Companies Mentioned        Enquire before Buying    Send to a Friend   There are more than 70 different sleep disorders but the most common ones include insomnia, sleep apnea, restless legs syndrome, and narcolepsy. One of the fastest growing sector in the sleep disorder treatment market is obstructive sleep apnea (OSA) products. OSA affects up to 18 million patients in the US with as many as 85% are undiagnosed. Similarly, 30 million are chronic sufferers of insomnia but only a third of chronic sufferers are receiving treatment. A key reason for this low percentage of people receiving treatment is the side effects associated with most of the insomnia drugs. Over 1.6 million Americans use some form of alternative medicine to treat insomnia. With rising awareness of sleep disorders, more people are undergoing tests to understand the basics of their sleep disorder condition. Hospitals are opening new sleep centres and upgrading old ones. Patients are looking at innovative aspects in sleep centres which make them feel more homely. Pharma companies are coming up with new sleeping disorder drugs. Gamma Aminobutyric Acid (GABA) agents dominate the insomnia market. More than a dozen insomnia drugs are in phase II and phase III clinical trials. Major products are Ambien, Ambien CR, Lunesta, Temazepam, and Zolpidem. Respironics and ResMed are the leading competitors in the continuous positive airway pressure (CPAP) market. The report analyzes the sleep disorder treatment market. The focus is on OSA and insomnia treatment products. The report also profiles the major companies, with a discussion of their key business strategies. It also analyzes the major market and demographic trends prevalent in the sleep disorder treatment market. Customers who bought this item also bought Undiagnosed Sleep Disorder Market Offers Growth Opportunities The Global Market For Sleep-Wake Disorders, 2005-2012: Trends, Opportunities, and Insights in A High-Value Cns Therapy Area The World Market For Sexual Disorders, 2005-2012: Traversing New Frontiers in Sexual Chemistry CNS Therapy Worldwide Market Survey: Analysis and Forecasts - Technology, Sales and Company Profiles CNS Therapy US Market Survey: Analysis and Forecasts - Technology, Sales and Company Profiles Bipolar Disorder: Can Competitive Advantage Be Established in a Challenging Market Strategic Perspectives 2001: Panic Disorder - Opportunities For Antidepressant Expansion Pipeline Insight: Bipolar Disorder - New Treatments for Bipolar Depression Set to Drive Near-term Growth

		Top of page

All rights reserved. � Copyright 2008 Research and Markets    Terms and conditions Privacy Policy Publishers Employment Opportunities Site Map Link to us Webmaster